Researcher Profile

Researcher Profile

Lisa McGregor, MD, PhD

Lisa McGregor, MD, PhD

Howard O. Jr. and Jean S. Beaver Professor of Pediatric Hematology/Oncology, Department of Pediatrics
Chief, Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Pediatric Cancer
lmm56@psu.edu

Research Interests

  • Neoplasms
  • Child
  • Neuroblastoma
  • Pediatrics
  • Irinotecan
  • Young Adult
  • Radiotherapy
  • Gefitinib
  • Survival
  • Pharmacokinetics
  • Oxaliplatin
  • Wilms Tumor

Clinical Trials

Umbrella Long-term Follow-up Protocol
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Neuroblastoma Biology Studies
Renal Tumor Classification, Biology, and Banking Study
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed or Refractory Solid Tumors or Hematologic Malignancies
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib (IbranceĀ®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
AGCT1532, Randomized Phase 3 Trial of Accelerated vs Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastic Germ Cell Tumors
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3Inhibitor Gilteritinib for Patients with FLT3 Mutations
Phase I Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid Tumors and Leukemias
A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Recent Publications

2022

Caru, M, Levesque, A, Rao, P, Dandekar, S, Terry, C, Brown, V, McGregor, L & Schmitz, K 2022, 'A scoping review to map the evidence of physical activity interventions in post-treatment adolescent and young adult cancer survivors', Critical Reviews in Oncology/Hematology, vol. 171, 103620. https://doi.org/10.1016/j.critrevonc.2022.103620

2020

Santana, VM, Sahr, N, Tatevossian, RG, Jia, S, Campagne, O, Sykes, A, Stewart, CF, Furman, WL & McGregor, LM 2020, 'A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors', Cancer, vol. 126, no. 8, pp. 1749-1757. https://doi.org/10.1002/cncr.32722
Rao, P, Segel, JE, McGregor, LM, Lengerich, EJ, Drabick, JJ & Miller, B 2020, 'Attendance at National Cancer Institute and Children's Oncology Group Facilities for Children, Adolescents, and Young Adults with Cancer in Pennsylvania: A Population-Based Study', Journal of Adolescent and Young Adult Oncology, vol. 9, no. 1, pp. 47-54. https://doi.org/10.1089/jayao.2019.0045

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)